Mundipharma's Levact gets EU recommendation for blood cancers and lymphoma
This article was originally published in Scrip
Executive Summary
Mundipharma has received a positive opinion from the EU's CHMP recommending approval of its chemotherapy drug Levact (bendamustine; licensed from Astellas) to treat patients with indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM).